Trial · NCT02420821
Results by group445
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 445
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population | Sunitinib | 69.6 | percentage of participants | ||
Percentage of Participants With Disease Progression as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death From Any Cause in Programmed Death-Ligand 1 (PD-L1)-Selected Population | Atezolizumab + Bevacizumab | 58.4 | percentage of participants | ||
| Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population | Sunitinib | 7.5 | 95% Confidence Interval 6.8 to 9.7 | months | |
| Progression-Free Survival (PFS) as Determined by the Investigator According to RECIST v1.1 in PD-L1-Selected Population | Atezolizumab + Bevacizumab | 11.2 | 95% Confidence Interval 8.6 to 14.3 | months | |
| Percentage of Participants Who Died of Any Cause in ITT Population | Sunitinib | 55.3 | percentage of participants | ||
| Percentage of Participants Who Died of Any Cause in ITT Population | Atezolizumab + Bevacizumab | 54.8 | percentage of participants | ||
| Overall Survival (OS) in ITT Population | Sunitinib | 35.3 | 95% Confidence Interval 28.6 to 42.1 | months | |
| Overall Survival (OS) in ITT Population | Atezolizumab + Bevacizumab | 36.1 | 95% Confidence Interval 31.5 to 42.3 | months | |
| Percentage of Participants Who Died of Any Cause in PD-L1-Selected Population | Sunitinib | 56.5 | percentage of participants | ||
| Percentage of Participants Who Died of Any Cause in PD-L1-Selected Population | Atezolizumab + Bevacizumab | 53.9 | percentage of participants | ||
| OS in PD-L1-Selected Population | Sunitinib | 31.6 | 95% Confidence Interval 23.3 to 42.1 | months | |
| OS in PD-L1-Selected Population | Atezolizumab + Bevacizumab | 38.7 | 95% Confidence Interval 29.0 to 49.7 | months | |
| Percentage of Participants With PD as Determined by an Independent Review Committee (IRC) According to RECIST v1.1 or Death From Any Cause in ITT Population | Sunitinib | 63.6 | percentage of participants | ||
| Percentage of Participants With PD as Determined by an Independent Review Committee (IRC) According to RECIST v1.1 or Death From Any Cause in ITT Population | Atezolizumab + Bevacizumab | 60.4 | percentage of participants | ||
| PFS as Determined by an IRC According to RECIST v1.1 in ITT Population | Sunitinib | 8.3 | 95% Confidence Interval 7.0 to 9.7 | months | |
| PFS as Determined by an IRC According to RECIST v1.1 in ITT Population | Atezolizumab + Bevacizumab | 9.6 | 95% Confidence Interval 8.3 to 11.5 | months | |
| Percentage of Participants With PD as Determined by an IRC According to RECIST v1.1 or Death From Any Cause in PD-L1-Selected Population | Sunitinib | 64.7 | percentage of participants | ||
| Percentage of Participants With PD as Determined by an IRC According to RECIST v1.1 or Death From Any Cause in PD-L1-Selected Population | Atezolizumab + Bevacizumab | 62.9 | percentage of participants | ||
| PFS as Determined by an IRC According to RECIST v1.1 in PD-L1-Selected Population | Sunitinib | 7.2 | 95% Confidence Interval 6.1 to 11.1 | months | |
| PFS as Determined by an IRC According to RECIST v1.1 in PD-L1-Selected Population | Atezolizumab + Bevacizumab | 8.9 | 95% Confidence Interval 6.9 to 12.5 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02420821/results